CA2352436C - Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition - Google Patents

Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition Download PDF

Info

Publication number
CA2352436C
CA2352436C CA2352436A CA2352436A CA2352436C CA 2352436 C CA2352436 C CA 2352436C CA 2352436 A CA2352436 A CA 2352436A CA 2352436 A CA2352436 A CA 2352436A CA 2352436 C CA2352436 C CA 2352436C
Authority
CA
Canada
Prior art keywords
telmisartan
organic solvent
process according
water
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2352436A
Other languages
French (fr)
Other versions
CA2352436A1 (en
Inventor
Heinrich Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2352436A1 publication Critical patent/CA2352436A1/en
Application granted granted Critical
Publication of CA2352436C publication Critical patent/CA2352436C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

The invention relates to polymorphs of 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.

Description

Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition The invention relates to polymorphs of 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-l-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), particularly the polymorphic form B, mixtures of the polymorphs, processes for preparing telmisartan containing form B and the use thereof for preparing a pharmaceutical composition.

Background of the invention The compound telmisartan is known from European Patent EP 502 314 Bl and has the following chemical structure:
Me I N Me \>
N
N o oH
I ~ \

(I) Telmisartan and the design physiologically acceptable salts thereof have valuable pharmacological properties.
Telmisartan is an angiotensin antagonist, particularly an angiotensin-II-antagonist which by virtue of its pharmacological properties may be used for example to treat hypertension and cardiac insufficiency, to treat ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), to prevent the progression of cardiac insufficiency after myocardial infarct, to treat diabetic neuropathy, glaucoma, gastrointestinal diseases and bladder diseases. Other possible therapeutic applications can be found in EP 502314 Bl, the contents of which are hereby referred to.

In the course of the synthesis of telmisartan, the final step of the synthesis comprises saponifying the tert.butyl ester (II) according to Diagram 1.

Me Me Me NMe Me NMe N N N
~-~ N O O -- JI ~ O OH
Diagram 1:
The corresponding experimental procedure which may be carried out on a laboratory scale can be found in EP
502314 Bl. Surprisingly, however, it proved to be simple to transfer the method of synthesis already known to a large-scale industrial manufacturing process. The telmisartan synthesised on an industrial scale according to Diagram 1 is obtained after working up in the form of a product which has to be subjected to a further crystallisation step to complete the purification. In this obligatory crystallisation step the morphology of the end product which crystallises out leads to unforeseen problems.

The product which is precipitated as a solid in the form of long needles is difficult to filter, wash and isolate, is further characterised by a very long drying time on account of the presence of solvent and forms large, very hard fragments during the drying process. Grinding these fragments produces a dry powder which exhibits a strong tendency to electrostatic charging and is virtually impossible to pour.
The disadvantageous properties of a product as described above have always proved to be a serious obstacle to the large-scale manufacture of a compound, as reproducible manufacture of large amounts of the compound in highly pure form is only possible with considerable difficulty or with high additional technical costs.

The aim of the present invention is therefore to prepare telmisartan in a form which permits the large-scale synthesis, working up, purification and isolation of telmisartan in which the above disadvantages are overcome.

Detailed description of the invention Surprisingly, it has been found that telmisartan may occur as a solid in different crystalline modifications.
Depending on the nature of the crystallisation process it may be converted into two different polymorphic forms A
and B.
Polymorph A is a form of telmisartan which is obtainable according to the prior art, and which gives rise to the abovementioned problems in large-scale manufacture or purification, isolation and drying of the product.
The polymorphic form B of telmisartan which was surprisingly found, however, shows virtually no tendency to electrostatic charging, is easy to suction filter, centrifuge, wash and dry and is free-flowing even without being ground up.

- 3a -According to one aspect of the present invention, there is provided polymorphic crystal modification B (form B) of telmisartan (formula I), Me Me N Me \ \~
N
I / N OH
N

(I) characterised by an endothermic maximum at 183 2 C which occurs during thermal analysis using DSC.

According to another aspect of the present invention, there is provided process for preparing the form B of telmisartan described herein or telmisartan described herein, wherein:

a) telmisartan is taken up in a mixture of solvents consisting of water, formic acid and an organic solvent miscible therewith, heated, and the resulting solution is then filtered; b) the organic solvent is distilled off, and water is optionally added during the distillation in an amount substantially corresponding to the amount of the organic solvent distilled off; c) the telmisartan form B is precipitated out of the remaining solution by the addition of a base; and d) the product precipitated is centrifuged, washed and dried.

The following procedure is used according to the invention to prepare the polymorphic form B of telmisartan.

Crude telmisartan product (crystallized for example from dimethylformamide, dimethylacetamide or the like) is taken up, in a suitably sized stirring apparatus, optionally with 1-5 wt.-a, preferably with 3 wt.-o of activated charcoal in a mixture of solvents consisting of water, formic acid and a suitable organic solvent and then dissolved at elevated temperature, preferably at a temperature of from 50-90 C, most preferably at 60-80 C.
According to the invention it is essential to use the solvent mixture of formic acid and water with an organic solvent which must satisfy the following criteria according to the invention. It must be capable of forming a solution with the mixture of formic acid and water. It must be largely chemically inert relative to the mixture of formic acid and water and it must be capable of being separated from the mixture of formic acid and water by distillation. Organic carboxylic acid esters, ketone or ethers may be used. Acetone, methylethylketone, methyl acetate, ethyl acetate, ethyl formate, ethyleneglycol dimethylether or tetrahydrofuran may be mentioned by way of example. Acetone, methylethylketone, methyl acetate, ethyl acetate and THF are preferred according to the invention, while ethyl acetate is particularly preferred.
According to the invention, the mixture of solvents should be made up of 0.3-0.7 1 of water, 10-15 mol of formic acid and 0.3-0.9 1 of the organic solvent per mol of telmisartan. A ratio of 0.4-0.6 1 of water, 11-13 mol of formic acid and 0.4-0.7 1 of the organic solvent based on 1 mol of telmisartan is preferred. A ratio of about 0.5 1 of water, about 11.5-12 mol of formic acid and about 0.5 1 of the organic solvent based on 1 mol of telmisartan is particularly preferred.

According to the invention, after the abovementioned heating, the solution obtained is filtered and washed with a mixture of the abovementioned organic solvent and formic acid. The washing solution may contain 0.3-1.0 mol, preferably 0.4-0.6 mol, most preferably about 0.5 mol of formic acid per mol of telmisartan. The quantity of washing solution will naturally depend on the quantity of dissolved telmisartan. According to the invention, 0.1-0.4, preferably 0.15-0.3, most preferably 0.2 1 of the organic solvent are used to each mol of telmisartan.

After the filter residue has been washed with the washing solution described above, the organic solvent is distilled off as much as possible whilst water is added simultaneously. The temperature is kept in the range from 60-100 C, preferably from 70-100 C. The total quantity of water added corresponds substantially to the total amount of solvent distilled off. Almost total distillation of the organic solvent is desirable according to the invention.
Accordingly, the distillation is continued until water is also distilled off, partly azeotropically. The organic solvent distilled off may be used again in subsequent reactions, if necessary after removal of the aqueous phase.

In order to precipitate the telmisartan-polymorphic B it is then cooled to a temperature in the range from 15-60 C, preferably to 20-30 C, and precipitated with a base. The quantity of base to be used depends on the amount of formic acid used. Preferably, 0-2 mol less base is added than there is formic acid present. Most preferably, 0.3-1.5 mol less base is added than there is formic acid present. It is most particularly preferred to add 0.5-1 mol less base than there is formic acid present. Suitable bases might be either aqueous solutions of potassium hydroxide, sodium hydroxide, lithium hydroxide or ammonia.
It is also possible to use suitable organic bases such as triethylamine, diisopropylethylamine or DBU
(diazabicycloundecene). Particularly preferred bases are the abovementioned aqueous solutions of the potassium hydroxide, sodium hydroxide, lithium hydroxide or ammonia, the aqueous solutions of ammonia being particularly important.
The product precipitated is centrifuged, washed with water and normally dried in vacuo at 120-125 C.
A sample taken directly after centrifuging and dried in a thin layer in a circulating air drier in the laboratory typically shows a content of 95-99% of crystalline form B.
After centrifugation, the product begins to change partially into form A, depending on the temperature, pH, retention time, and water content, towards the end of the drying. Therefore, in working mixtures, ratios of form A
to form B of at best about 10:90 are obtained after drying, but ratios of 60:40 may also be obtained.
However, even a content of form B as low as this guarantees that the product will have the positive qualities required for large-scale production (e.g. a low tendency to electrostatic charging, a low tendency to clumping, free-flowing characteristics etc.). What is essential to the invention in the crystallisation process mentioned above is that initially only form B is produced, with its characteristic macroscopic crystalline form. This macroscopic crystalline form is largely retained under the drying conditions, in spite of partial microscopic rearrangement into form A.

Other highly advantageous aspects of the procedure according to the invention are the high space/time yield of the present process and the high yield of pure telmisartan product, which can be isolated in virtually quantitative amounts.

The telmisartan of form A which can be obtained by the manufacturing process known from the prior art differs from the telmisartan obtainable according to the invention, which is characterised in that it contains some polymorphic form B, in the advantageous qualities of the product already mentioned hereinbefore. Other distinguishing features will be described hereinafter.

Telmisartan of form A crystallises as long, fine or thin needles which cling together in a felt-like manner. The crystal modification of telmisartan of form B produces very compact cubic to spherical crystals which trickle like sand or silica gel.
The two polymorph forms A and B of telmisartan differ considerably in their melting point. Form B melts at 183+/-2 C (determined by DSC), form A at 269+/-2 C
(determined by DSC). After melting, the lower-melting form B of telmisartan crystallises out again as form A. This results, for example, in the endothermic maximum at 183+/-2 C determined by DSC being followed by a characteristic exothermic maximum which reflects the crystallisation of the melt of form B into the high-melting form A. The DSC
diagrams (DSC=Differential Scanning Calorimetry) obtained TM
with a Mettler DSC-20, TA8000 system are shown in Figure 1.

The polymorphs A and B also differ in their IR spectrum.
On the basis of this difference, the IR spectroscopy may optionally be used for quantitative determination of the ratio of the two crystal modifications in the end product after drying. Pure polymorph A has a characteristic band at 815cm-1 in the IR spectrum. In polymorph B this oscillation is_shifted to 830cm -1. Since these two characteristic bands of polymorphs A and B are sufficiently far apart, they are particularly suitable for the abovementioned quantitative determination of the ratio of the two crystal modifications.
The IR-spectroscopic characterisation of the two polymorphic forms A and B was carried out using the Nicolet FTIR Spectrometer Magna - IR 550 in KBr (2.S mol per 300 mg KBr; Nicolet software package OMNIC, version 1.20).

The Examples which follow serve to illustrate purification and crystallisation processes carried out by way of example in order to prepare the polymorphic form B of telmisartan. They should be regarded purely as possible procedures described by way of example, without restricting the invention to their contents.
Example 1 205.6 kg of recrystallised telmisartan (recrystallised from dimethylformamide or dimethylacetamide), 6.2 kg of activated charcoal, 205.6 1 of water, 211.6 kg of formic acid (99-100%) and 205.6 1 of ethyl acetate are placed in a 1200 1 stirring apparatus. The mixture is stirred for about 1 h at 70 - 80 C and then filtered into another 1200 1 stirring apparatus and washed with a mixture of 82.2 1 of ethyl acetate and 9.2 kg of formic acid (99-1000). About 308 1 of solvent are distilled off at 80 -100 C whilst simultaneously 308 1 of water are added. The mixture is then cooled to 20 - 30 C and precipitated by the metered addition of 313 kg of 25 % ammonia solution.
The product precipitated is centrifuged, washed with water and dried at 120-125 C.
Yield : 200 kg telmisartan (97.3 a of theory) Example 2 185 kg of recrystallised telmisartan (recrystallised from dimethylformamide or dimethylacetamide), 5.6 kg of activated charcoal, 185 1 of water, 190.4 kg of formic acid (99-100%) and 185 1 of tetrahydrofuran are placed in a 1200 1 stirring apparatus. The mixture is stirred for . CA 02352436 2001-05-28 about 1 h at 60 - 70 C and then filtered into another 1200 1 stirring apparatus and washed with a mixture of 74 1 of tetrahydrofuran and 8.3 kg of formic acid (99-1000).
About 278 1 of solvent are distilled off at 70 - 100 C
whilst simultaneously 278 1 of water are added. The mixture is then cooled to 20 - 30 C and precipitated by the metered addition of 281.5 kg of 25 % ammonia solution.
The product precipitated is centrifuged, washed with water and dried at 120-125 C.
Yield : 180 kg telmisartan (97.3 % of theory) f ^' Example 3 185 kg of recrystallised telmisartan (recrystallised from dimethylformamide or dimethylacetamide), 5.6 kg of activated charcoal, 185 1 of water, 190.4 kg of formic acid (99-100%) and 185 1 of methylethylketone are placed in a 1200 1 stirring apparatus. The mixture is stirred for about 1 h at 60 - 70 C and then filtered into another 1200 1 stirring apparatus and washed with a mixture of 74 1 of methylethylketone and 8.3 kg of formic acid (99-1000). About 278 1 of solvent are distilled off at 80 -100 C whilst simultaneously 278 1 of water are added. The mixture is then cooled to 20 - 30 C and precipitated by the metered addition of 281.5 kg of 25 % ammonia solution.
The product precipitated is centrifuged, washed with water and dried at 120-125 C.
Yield : 178 kg of telmisartan (96.2 % of theory) Comparison Example 150 kg of telmisartan (recrystallised from dimethylformamide or dimethylacetamide), 7.5 kg of activated charcoal, 750 1 of ethanol and 30 kg of 25%
aqueous ammonia solution are placed in a 1200 1 stirring apparatus. The mixture is stirred for about 1 h and then filtered into another 1200 1 stirring apparatus and washed with 150 1 of ethanol. The mixture is heated to 70 -80 C, 35 kg of glacial acetic acid are added and the mixture is stirred for a further 1.5 - 2 h at 75 - 80 C.
The mixture is then cooled to 0 - 10 C and stirred for a further 2 h. The product precipitated is centrifuged, washed with 300 1 of ethanol and with 300 1 of water and dried at 70 - 90 C.
Yield : 135 kg of telmisartan (90 % of theory) pure form A
In the preparation process according to the invention, as a result of the partial conversion of the polymorphic form B into the polymorphic form A during the drying process, telmisartan occurs as a pure substance in a mixture of two polymorphic forms. However, this does not affect the properties of the pharmaceutical composition, as in the course of the manufacture of telmisartan tablets, for example, the mixture of the polymorphic forms A and B is dissolved in 0.1 N NaOH solution and converted by spray drying into a homogeneous and totally amorphous granulate which is then subjected to the other tablet making steps.
For more detailed information on the use of the products according to the invention for preparing a pharmaceutical composition, cf. EP 502314 B1, the contents of which are hereby referred to.

Claims (9)

CLAIMS:
1. Polymorphic crystal modification B (form B) of telmisartan (formula I), characterised by an endothermic maximum at 183~2°C which occurs during thermal analysis using DSC.
2. Telmisartan comprising the form B of telmisartan defined in claim 1.
3. Process for preparing the form B of telmisartan defined in claim 1 or telmisartan as defined in claim 2, wherein:

a) telmisartan is taken up in a mixture of solvents consisting of water, formic acid and an organic solvent miscible therewith, heated, and the resulting solution is then filtered;

b) the organic solvent is distilled off, and water is optionally added during the distillation in an amount substantially corresponding to the amount of the organic solvent distilled off;

c) the telmisartan form B is precipitated out of the remaining solution by the addition of a base; and d) the product precipitated is centrifuged, washed and dried.
4. Process according to claim 3, wherein the organic solvent is one or more solvents selected from the group consisting of organic carboxylic acid esters, ketones and ethers.
5. Process according to claim 3, wherein the organic solvent is acetone, methylethylketone, methyl acetate, ethyl acetate, ethyl formate, ethyleneglycol dimethylether or tetrahydrofuran.
6. Process according to claim 3, wherein the organic solvent is acetone, methylethylketone, methyl acetate, ethyl acetate or tetrahydrofuran.
7. Process according to claim 3, wherein the organic solvent is ethyl acetate.
8. Process according to any one of claims 3 to 7, wherein the base is ammonia.
9. A pharmaceutical composition comprising form B of telmisartan as defined in claim 1 or telmisartan as defined in claim 2 and a pharmaceutically acceptable carrier.
CA2352436A 1999-01-19 2000-01-07 Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition Expired - Fee Related CA2352436C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19901921A DE19901921C2 (en) 1999-01-19 1999-01-19 Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament
DE19901921.5 1999-01-19
PCT/EP2000/000065 WO2000043370A1 (en) 1999-01-19 2000-01-07 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament

Publications (2)

Publication Number Publication Date
CA2352436A1 CA2352436A1 (en) 2000-07-27
CA2352436C true CA2352436C (en) 2010-03-23

Family

ID=7894715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2352436A Expired - Fee Related CA2352436C (en) 1999-01-19 2000-01-07 Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition

Country Status (36)

Country Link
EP (1) EP1144386B1 (en)
JP (1) JP4700813B2 (en)
KR (1) KR100658959B1 (en)
CN (1) CN1144790C (en)
AR (1) AR035475A1 (en)
AT (1) ATE252564T1 (en)
AU (1) AU765081B2 (en)
BG (1) BG65027B1 (en)
BR (1) BR0007584A (en)
CA (1) CA2352436C (en)
CO (1) CO5150238A1 (en)
CZ (1) CZ297412B6 (en)
DE (2) DE19901921C2 (en)
DK (1) DK1144386T3 (en)
EA (1) EA003065B1 (en)
EE (1) EE04344B1 (en)
ES (1) ES2208265T3 (en)
HK (1) HK1041485B (en)
HR (1) HRP20010514B1 (en)
HU (1) HU227401B1 (en)
IL (2) IL143634A0 (en)
MY (1) MY122755A (en)
NO (1) NO319823B1 (en)
NZ (1) NZ513528A (en)
PE (1) PE20001362A1 (en)
PL (1) PL211829B1 (en)
PT (1) PT1144386E (en)
RS (1) RS50044B (en)
SA (1) SA99200838B1 (en)
SK (1) SK285429B6 (en)
TR (1) TR200102074T2 (en)
TW (1) TWI280241B (en)
UA (1) UA56358C2 (en)
UY (1) UY25980A1 (en)
WO (1) WO2000043370A1 (en)
ZA (1) ZA200104771B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
DE10153737A1 (en) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
DK1854454T3 (en) 2002-01-16 2014-01-13 Boehringer Ingelheim Pharma Process for the preparation of amorphous telmisartan
DE10314702A1 (en) 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of telmisartan
GB2414019A (en) * 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
KR20080112424A (en) 2004-10-15 2008-12-24 테바 파마슈티컬 인더스트리즈 리미티드 Process for preparing telmisartan
US7943781B2 (en) 2004-10-18 2011-05-17 Dr. Reddy's Laboratories Limited Process for preparing telmisartan
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
EP2432452B1 (en) 2009-05-20 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical telmisartan drink solution
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
WO2011002425A2 (en) 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EA025946B1 (en) 2010-10-27 2017-02-28 Крка, Товарна Здравил, Д. Д., Ново Место Multilayer pharmaceutical composition comprising telmisartan and amlodipine
ITMI20102416A1 (en) * 2010-12-27 2012-06-28 Chemelectiva S R L INTERMEDIATE FOR THE PREPARATION OF AN ACTIVE PRINCIPLE AND PROCESS FOR ITS PREPARATION
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
JP6147546B2 (en) * 2013-04-10 2017-06-14 株式会社トクヤマ Method for producing telmisartan A-type crystals with reduced acetic acid
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
JP6275596B2 (en) * 2014-09-03 2018-02-07 株式会社トクヤマ Method for producing ammonium salt of telmisartan
JP5871294B1 (en) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Immediate release oral tablets
KR20170001921A (en) 2015-06-26 2017-01-05 대원제약주식회사 A pharmaceutical composition comprising telmisartan with increased stability and a preparation method thereof
KR20170012703A (en) 2015-07-22 2017-02-03 대원제약주식회사 A pharmaceutical composition comprising telmisartan and a preparation method thereof
WO2017207375A1 (en) 2016-05-30 2017-12-07 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
KR102044223B1 (en) * 2016-09-12 2019-11-13 성균관대학교산학협력단 Solid dispersions comprising Telmisartan and the preparation method thereof
CN106749037B (en) * 2016-12-21 2019-06-21 山东大学 A kind of unformed Telmisartan-glutaric acid eutectic and its preparation method and application
CN106749036B (en) * 2016-12-21 2019-06-21 山东大学 A kind of unformed Telmisartan-pimelic acid eutectic and its preparation method and application
CA3067918A1 (en) 2017-07-07 2019-01-10 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats
CN109851562A (en) * 2019-01-30 2019-06-07 浙江省食品药品检验研究院 A kind of Telmisartan crystal and preparation method thereof
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5139114A (en) * 1991-03-18 1992-08-18 Abex Corporation Visible brake block wear indicator

Also Published As

Publication number Publication date
UY25980A1 (en) 2001-08-27
HRP20010514B1 (en) 2010-01-31
DK1144386T3 (en) 2004-01-12
EE04344B1 (en) 2004-08-16
YU51101A (en) 2004-05-12
IL143634A (en) 2006-10-05
SA99200838B1 (en) 2006-03-06
PL349425A1 (en) 2002-07-29
WO2000043370A1 (en) 2000-07-27
KR100658959B1 (en) 2006-12-19
BG65027B1 (en) 2006-12-29
HU227401B1 (en) 2011-05-30
DE19901921C2 (en) 2001-01-04
AR035475A1 (en) 2004-06-02
AU2288100A (en) 2000-08-07
ES2208265T3 (en) 2004-06-16
CZ297412B6 (en) 2006-12-13
SK285429B6 (en) 2007-01-04
BR0007584A (en) 2001-11-06
AU765081B2 (en) 2003-09-11
BG105654A (en) 2002-01-31
HK1041485B (en) 2004-10-08
HK1041485A1 (en) 2002-07-12
IL143634A0 (en) 2002-04-21
CA2352436A1 (en) 2000-07-27
PT1144386E (en) 2004-03-31
DE50004150D1 (en) 2003-11-27
NZ513528A (en) 2003-08-29
MY122755A (en) 2006-05-31
PL211829B1 (en) 2012-06-29
TR200102074T2 (en) 2001-12-21
EA003065B1 (en) 2002-12-26
ZA200104771B (en) 2002-12-02
KR20010101552A (en) 2001-11-14
PE20001362A1 (en) 2000-12-15
NO319823B1 (en) 2005-09-19
EA200100730A1 (en) 2002-02-28
JP4700813B2 (en) 2011-06-15
CZ20012634A3 (en) 2001-10-17
EP1144386B1 (en) 2003-10-22
TWI280241B (en) 2007-05-01
EE200100375A (en) 2002-10-15
HUP0105148A2 (en) 2002-07-29
CN1336920A (en) 2002-02-20
CN1144790C (en) 2004-04-07
NO20013560L (en) 2001-09-18
CO5150238A1 (en) 2002-04-29
EP1144386A1 (en) 2001-10-17
UA56358C2 (en) 2003-05-15
DE19901921A1 (en) 2000-08-03
HUP0105148A3 (en) 2003-01-28
HRP20010514A2 (en) 2002-08-31
RS50044B (en) 2008-11-28
SK10202001A3 (en) 2001-12-03
NO20013560D0 (en) 2001-07-18
JP2002535315A (en) 2002-10-22
ATE252564T1 (en) 2003-11-15

Similar Documents

Publication Publication Date Title
CA2352436C (en) Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition
US6358986B1 (en) Polymorphs of telmisartan
JP5247728B2 (en) Method for producing benzimidazole derivative
FR2780403A1 (en) Novel crystalline structure of Irbestan Form A
KR20050118699A (en) Method for the production of telmisartan
CN110615788A (en) Preparation process of high-purity apixaban
WO2014096214A1 (en) A process for preparation of rivaroxaban
CN107935957A (en) A kind of method for synthesizing high-purity losartan side chain TTBB
CN110066233B (en) Preparation method of mono-substituted amine compound
MXPA01006995A (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
CN106279108B (en) A kind of method of industrialized production Rabeprazole and dextral-rabeprazole intermediate
CN111574463A (en) Riagliptin intermediate compound IV
CN111574520A (en) Riagliptin intermediate compound V
US11932614B2 (en) Method for preparing diazoxide
CN116041372A (en) Sulfur-nitrogen heterocyclic alkane intermediate compound, preparation method and application thereof
CN113480484A (en) Preparation method of medical intermediate

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160107